OTC Medicines

(Washington, D.C.) – Consumer Healthcare Products Association (CHPA) Senior Vice President of Regulatory and Scientific Affairs Lisa Parks released the following statement today regarding the U.S. Food and Drug Administration’s

CHPA released a statement after submitting a Citizen Petition to the U.S. Federal Trade Commission (FTC) urging it to withdraw the Notice of Penalty Offenses Concerning Substantiation of Product Claims.

CHPA expresses disappointment in the recent NDAC recommendation and encourages FDA to consider the total weight of evidence before making any regulatory changes.

CHPA's most current statement on the recent meeting of the FDA Nonprescription Advisory Committee (NDAC) to evaluate the efficacy of oral phenylephrine (PE).

CHPA echoed concerns in a letter sent to the U.S. Food and Drug Administration by U.S. Reps. Bob Latta (OH-05), Debbie Dingell (MI-06), and Dan Crenshaw (TX-02), urging the Agency to ensure the simultaneous marketing provision of its proposed rule for Nonprescription Drug Product With an Additional Condition for Nonprescription Use is not included in a final rule.

The Consumer Healthcare Products Association Educational Foundation today released the following statement announcing the 2023 U.S. Self-Care Marketing Awards finalists. Winners will be announced at the Eighth Annual CHPA Educational Foundation Gala on November 15 at The Bellevue Hotel in Philadelphia. Specific awards will recognize the strategic innovation and marketing expertise of CHPA member companies in the OTC medicine, consumer medical device, and dietary supplement industries.